CMB International Securities | Equity Research | Company Update

# **Redsun Services (1971 HK)** FY20 earnings beat, with quality M&As to kickstart scale expansion

Redsun Services delivered strong FY20 results with core earnings up 63% to RMB93mn (beating our estimates by 10%). Management guides 50% revenue/net profit CAGR up to 2023, and we could see 60% earnings growth in 2021E as Redsun's acquisition of Wuhan Huidehang may boost earnings by 30%. As for 2022E/23E, the Company may rely more on 3<sup>rd</sup>-party expansion which may contribute 30-40% of new contracted GFA (vs. 15% in 2020) as well as VAS. We raise earnings forecast for 2022E/23E by 7.9%/12.7% and **maintain BUY** on Redsun as an attractive name among small players.

- Redsun delivered strong 2020 results. Managed GFA was up 71% to 27mn sq m, with 52% from third-party (2019: 30%). Revenue grew 53% YoY to RMB768mn driven by strong VAS performance (+311% YoY). Segment wise, basic PM growth (+40% YoY) was slower than expected but VAS acceleration exceeded our expectations, contributing to 14% of revenue, closing in on industry average of ~15%. At bottom line, core profit (excl. listing expenses) grew 63% YoY, beating our estimates by 10%. The Company declared a dividend of RMB0.05/share, representing 31% payout ratio.
- Management guides 50% revenue/NP CAGR in next three years. Company guided 50% revenue/NP CAGR in the next three years, and aimed for 60% of managed GFA to come from third-party (incl. M&A) by 2023. We see some uncertainties on third-party execution, but community VAS should sustain high growth due to AM services (car-park sales, 44% of 2020 VAS revenue) having 3-4 years of sellable reserve. Furthermore, we think many of Redsun's initiatives, such as commercial projects, new VAS tryouts in community retail, and city services can be promising.
- Some M&A to accelerate scaling, but recent acquisitions have been margin accretive. The Company suggests 60% of third-party GFA gain in 2021 will come from M&A. However, we think there is less of the usual concern on M&A quality, because Redsun's acquisitions since IPO have been profitable (2020 NPM: Wuhan Huidehang - 24%, Chuzhou Yurun - 12%, vs. 12% of Redsun), and Redsun plans to focus its M&A effort in the YRD where PM fees are generally higher with less chance of margin dilution.
- Raise 2021E/22E earnings forecast and Maintain BUY. We raise 2021E/22E earnings by 7.9%/12.7%. Currently Redsun trades at 6.3x 2022E P/E vs. industry average 15x, which is quite attractive. Maintain BUY.

## **Earnings Summary**

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	503	768	1,354	2,010	2,814
YoY growth (%)	44.1	52.7	76.4	48.4	0.0
Core Profit (RMB mn)	59	93	164	242	342
YoY growth (%)	N.A.	0.17	0.40	0.58	0.82
EPS (RMB)	N.A.	N.A.	135.1	47.7	40.8
Consensus EPS (RMB)	N.A.	0.19	0.36	0.55	N.A.
P/E (x)	N.A.	22.0	9.4	6.3	4.5
P/B (x)	N.A.	2.1	2.8	2.5	2.1
Yield (%)	N.A.	1.4	3.2	4.7	6.7
ROE (%)	28.4	10.1	31.7	44.3	52.9

Source: Company data, Bloomberg, CMBIS estimates



## **BUY (Maintain)**

Target Price	HK\$9.37
(Previous TP	HK\$9.37)
Up/Downside	+110.1%
Current Price	HK\$4.46

#### **China Property Service Sector**

Bowen Li (852) 3657 6239 bowenli@cmbi.com.hk

Jeffrey Zeng (852) 3916 3727

jeffreyzeng@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	1,851
Avg 3 mths t/o (HK\$ mn)	4.72
52w High/Low (HK\$)	7.72/4.08
Total Issued Shares (mn)	415
Source: Bloomberg	


**Shareholding Structure** 

Redsun Group	72.8%
Free float	27.2%
Source: HKEx	

#### Share Performance

	Absolute	Relative
1-mth	1.1%	8.7%
3-mth	-7.3%	-14.3%
6-mth	-21.0%	-34.2%
12-mth	N.A.	N.A.
Source: Bloomberg		

#### **12-mth Price Performance**



Source: Bloomberg

Auditor: Ernst & Young




## Figure 1: Earnings revision

	Ne	W	0	ld	Difference	
RMB mn	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Revenue	1,354	2,010	1,146	1,541	18.2%	30.4%
Gross Profit	389	590	319	440	22.0%	34.2%
Operating profit	231	347	206	293	12.3%	18.5%
Net profit	164	242	152	215	7.9%	12.7%
Gross Margin	28.7%	29.4%	27.8%	28.6%	0.9 ppt	0.8 ppt
Operating margin	17.1%	17.3%	18.0%	19.0%	-0.9 ppt	-1.7 ppt
Net Margin	12.1%	12.1%	13.3%	14.0%	-1.2 ppt	-1.9 ppt


Source: Company data, CMBIS estimates

### Figure 2: Revenue




Source: Company data, CMBIS estimates






Source: Company data, CMBIS estimates

## Figure 3: Gross profit margin



Source: Company data, CMBIS estimates

## Figure 5: Adjusted net profit



Source: Company data, CMBIS estimates



## **Financial Summary**

YE Dec 31 (Rmb mn)	FY19A	FY20A	FY21E	FY22E	FY23E	
Revenue	503	768	1,354	2,010	2,814	
Basic PM	355	496	896	1,288	1,726	
Non-owner VAS	121	161	193	232	279	
Community VAS	27	110	265	490	809	
Cost of sales	(376)	(554)	(965)	(1,419)	(1,970)	
Gross profit	127	214	389	590	844	
Other income, net	3	20	21	22	23	
Selling and marketing	(0)	(1)	(3)	(4)	(6)	
Administrative expenses	(51)	(104)	(176)	(261)	(366)	
Other expenses	(0)	-	-	-	-	
Impairment	(0)	(2)	-	-	-	
Operating profit	78	108	231	347	495	
Share from associates	-	-	-	-	-	
Finance costs	(0)	(0)	-	-	-	
Exceptional	0	(19)	-	-	-	
Pre-tax Profit	78	108	231	347	495	
Income tax	(21)	(35)	(58)	(87)	(124)	
PROFIT FOR THE YEAR	57	73	174	260	372	
Non-controlling interest	2	(4)	(10)	(18)	(30)	
Net profit to shareholders	59	70	164	242	342	
Balance sheet						
YE Dec 31 (Rmb mn)	FY19A	FY20A	FY21E	FY22E	FY23E	
Non-current assets	37	91	202	263	324	

	Cash flow summary					
Ε	YE Dec 31 (Rmb mn)	FY19A	FY20A	FY21E	FY22E	FY23E
4	Profit before tax	78	108	231	347	495
6	D&A	3	1	2	2	2
9	Chg in working capital	34	3	(138)	245	157
9	Others	(4)	(35)	(58)	(87)	(124)
))	Net cash from operating	111	77	37	507	531
4		-	-	-	-	-
	FA Capex & Inv, net	(4)	(3)	(3)	(3)	(3)
3	Associated companies	(55)	(37)	(366)	(200)	(200)
5)	Others	31	-	-	-	-
5)	Net cash from investing	(28)	(40)	(369)	(203)	(203)
-						
-	Equity raised	99	460	-	-	-
5	Chg of debts	(5)	-	-	-	-
	Others	(35)	117	13	(73)	(104)
-	Net cash from financing	58	577	13	(73)	(104)
-	_					
-	Net change in cash	141	615	(318)	232	224
	Cash at the beginning of the	38	179	794	476	708
5	Cash at the end of the year	179	794	476	708	932
		-		-	-	
)	Key ratios					
2	YE Dec 31	FY19A	FY20A	FY21E	FY22E	FY23E

70.5

64.6

66.2

64.1

61.4

Net profit to shareholders			104	<b>7</b> 4	042	Dusion M	10.0	04.0	00.2	04.1	01.4
						Non-owner VAS	24.1	21.0	14.3	11.5	9.9
						Community VAS	5.3	14.4	19.6	24.4	28.7
Balance sheet						Total	100.0	100.0	100.0	100.0	100.0
YE Dec 31 (Rmb mn)	FY19A	FY20A	FY21E	FY22E	FY23E						
Non-current assets	37	91	202	263	324	Profit & loss ratios (%)					
PP&E	9	14	52	73	94	Gross margin	25.3	27.9	28.7	29.4	30.0
Goodwill	12	31	68	88	108	Operating margin	15.6	14.1	17.1	17.3	17.6
Others	15	46	82	102	122	Net margin	11.7	9.1	12.1	12.1	12.1
						Effective tax rate	27.1	32.4	25.0	25.0	25.0
Current assets	503	1,017	913	1,090	1,391						
Trade receivables	26	72	383	329	404	Growth (%)					
Due from related	263	88	23	23	24	Revenue	44.1	52.7	76.4	48.4	40.0
Cash and cash equivalents	179	826	476	708	932	Gross profit	82.7	68.2	81.5	51.8	42.9
Others	35	30	30	30	30	EBIT	73.4	38.2	113.4	50.1	42.7
						Net profit	79.0	18.1	135.1	47.7	41.1
Total Asset	540	1,108	1,116	1,353	1,715						
						Balance sheet ratios					
Current liabilities	320	377	549	739	971	Current ratio (x)	1.6	2.7	1.7	1.5	1.4
Payables & accruals	172	222	395	585	818	Receivable turnover days	19	34	34	34	34
Due to related companies	38	2	-	-	-	Payables turnover days	42	32	32	32	32
Interest-bearing bank	-	-	-	-	-	Inventory turnover days	0.02	0.03	0.03	0.03	0.03
Others	110	153	153	153	153	Net debt / total equity ratio (%)	Net	Net	Net	Net	Net
Non-current liabilities	2	10	10	10	10	Returns (%)					
Deferred taxes liabilities .	2	10	10	10	10	ROE	28.4	10.1	31.7	44.3	52.9
						ROA	10.6	6.6	15.6	19.2	21.7
Total liabilities	322	387	559	749	982						
						Per share					
Equity to shareholders	208	690	517	546	646	EPS (RMB)	n.a.	0.17	0.40	0.58	0.82
Non-controlling interests	9	30	40	58	88	DPS (RMB)	n.a.	0.05	0.12	0.18	0.25
Total Equity	217	720	557	604	733	BVPS (RMB)	n.a.	1.74	1.34	1.46	1.76

Sales mix (%) Basic PM

Source: Company data, CMBIS estimates





## **Disclosures & Disclaimers**

### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

#### Disclosure

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIS Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon reguest.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.